
Renal Cell Carcinoma
Latest News
Latest Videos

CME Content
More News

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.

IVS-3001, a chimeric antigen receptor therapy developed to target and kill HLA-G-bearing cells, is currently in late-stage preclinical development for the treatment of solid tumors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tian Zhang, MD, and participants discussed factors that drive their choice of first-line therapy for patients with advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro Barata, MD, MSc, discussed the CheckMate 9ER, KEYNOTE-426, and CLEAR trials of frontline combination therapies for patients with renal cell carcinoma.

In the second article of a 2-part series, Hans Hammers, MD, PhD, leads a discussion on the adverse events seen with the use of tyrosine kinase inhibitors in the treatment of patients with renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Nizar M. Tannir, MD, discussed with participants their experiences with the combination of lenvatinib and pembrolizumab, including the dosing schedule of pembrolizumab and finding a tolerable dose of lenvatinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Campbell, MD, MS, discussed guidelines and available therapies for a patient who requires second-line treatment and beyond for metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, and participants discussed using immunotherapy plus tyrosine kinase inhibitor to treat advanced renal cell carcinoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology, Yann-Alexandre Vano, MD, discussed the implications of the findings from the phase 2 BIONIKK trial of second-line treatment for patients with metastatic RCC.

At a live, virtual Case-Based Roundtable meeting, Bradley McGregor, MD, discussed with fellow physicians how best to integrate new approaches to treatment for patients with relapsed or refractory clear cell renal cell carcinoma.

In the fifth article of this series, Hans Hammers, MD, PhD, outlines established treatment paradigms and discusses clinical trial data and ongoing research that are informing the future treatment landscape of advanced renal cell carcinoma.

During a Targeted Oncology™ Community Case Forum™ event, Hans Hammers, MD, discussed trials that shed light on the role of adjuvant therapies for patients with stage II and III renal cell carcinoma.

Samer A. Srour, MD, discusses the results of the phase 1 TRAVERSE trial of ALLO-316 in patients with advanced renal cell carcinoma.

Eric Singer, MD, discusses the relevant data that led to the approval of sunitinib in the adjuvant treatment setting for renal cell carcinoma.

In part 1 of a 2-part series, Hans Hammers, MD, PhD, discusses the current landscape for treating patients with advanced renal cell carcinoma who have had 1 or 2 prior therapies and how tivozanib fits into current treatment practices.





























